- Home
- SNES vs RLYB Comparison
SNES vs RLYB Comparison
Compare SNES & RLYB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SNES
- RLYB
- Stock Information
- Founded
- SNES 2004
- RLYB 2018
- Country
- SNES United States
- RLYB United States
- Employees
- SNES N/A
- RLYB N/A
- Industry
- SNES Agricultural Chemicals
- RLYB Biotechnology: Pharmaceutical Preparations
- Sector
- SNES Industrials
- RLYB Health Care
- Exchange
- SNES Nasdaq
- RLYB Nasdaq
- Market Cap
- SNES 24.0M
- RLYB 24.1M
- IPO Year
- SNES 2016
- RLYB 2021
- Fundamental
- Price
- SNES $3.77
- RLYB $0.61
- Analyst Decision
- SNES Strong Buy
- RLYB Hold
- Analyst Count
- SNES 1
- RLYB 2
- Target Price
- SNES $10.00
- RLYB N/A
- AVG Volume (30 Days)
- SNES 103.7K
- RLYB 283.6K
- Earning Date
- SNES 11-11-2025
- RLYB 11-07-2025
- Dividend Yield
- SNES N/A
- RLYB N/A
- EPS Growth
- SNES N/A
- RLYB N/A
- EPS
- SNES N/A
- RLYB N/A
- Revenue
- SNES $2,093,000.00
- RLYB $761,000.00
- Revenue This Year
- SNES $49.17
- RLYB N/A
- Revenue Next Year
- SNES $89.89
- RLYB N/A
- P/E Ratio
- SNES N/A
- RLYB N/A
- Revenue Growth
- SNES 36.89
- RLYB 154.51
- 52 Week Low
- SNES $1.30
- RLYB $0.22
- 52 Week High
- SNES $6.24
- RLYB $1.24
- Technical
- Relative Strength Index (RSI)
- SNES 42.31
- RLYB 61.83
- Support Level
- SNES $3.60
- RLYB $0.54
- Resistance Level
- SNES $3.90
- RLYB $0.57
- Average True Range (ATR)
- SNES 0.27
- RLYB 0.04
- MACD
- SNES -0.02
- RLYB 0.01
- Stochastic Oscillator
- SNES 20.48
- RLYB 93.92
About SNES SenesTech Inc.
SenesTech Inc is a United States-based biotech platform and research company engaged in developing technology for managing animal pest populations through fertility control. The company provides its solutions to the animal market, commercial markets, and food markets. It currently has two product lines of fertility control products: ContraPest and Evolve.
About RLYB Rallybio Corporation
Rallybio Corp is a clinical stage biotechnology company committed to identifying and accelerating the development of life-transforming therapies for patients with severe and rare disorders. The programs of the company are for the prevention of fetal and neonatal alloimmune thrombocytopenia, a potentially life-threatening rare disease that can cause uncontrolled bleeding in fetuses and newborns.